Phase 2 Leukaemia Trial, Recruiting NCT04033302 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT04033302
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 6 months of age.
  • People whose cancer cells have been confirmed, through laboratory testing, to carry a specific protein called CD7 (or similar surface proteins) on their surface.
  • People who are in generally good physical health, as measured by a standard health scoring system (called the Karnofsky scale), with a score above 80, and who have a life expectancy of more than 3 months.
  • People whose heart, liver, kidneys, and bone marrow are functioning well enough to meet specific laboratory test thresholds set by the trial (confirm exact values with trial site).
  • People whose blood haemoglobin level is at or above a minimum level set by the trial (confirm with trial site).
  • People for whom there are no medical reasons preventing a cell collection procedure.
  • People who are willing and able to understand the trial and provide written consent to participate.

Who may not be able to join:

  • People with a serious illness or medical condition — including an active, uncontrolled infection — that would make it unsafe to follow the trial's treatment plan.
  • People with an active bacterial, fungal, or viral infection that is not being adequately controlled by treatment.
  • People with a known HIV or Hepatitis C infection.
  • People who are pregnant or currently breastfeeding.
  • People who have used steroid medicines (glucocorticoids) for a whole-body (systemic) treatment within one week before entering the trial.
  • People who have previously received any gene therapy treatment.
  • People who, in the opinion of the trial investigators, may have difficulty following the trial's requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety of infusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov